INTERNATIONAL BIOTECH TRUST PLC ORD GBP0.25
Symbol: IBT
Streaming is not available when market closed. Some prices may be as at close of business from the previous working day.
Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.
Invest in this share within an ISA, JISA, SIPP or Investment Account
Past Performance
- 26th Apr 2020 to 26th Apr 202116.49%
- 26th Apr 2021 to 26th Apr 2022-8.84%
- 26th Apr 2022 to 26th Apr 20237.46%
- 26th Apr 2023 to 26th Apr 2024-2.61%
- 26th Apr 2024 to 26th Apr 2025-1.62%
Key Information
| Benchmark | Nasdaq Biotechnology |
| Sector | IT Biotechnology & Healthcare |
| Gearing | 100% |
| Ex-Dividend Date | 19 Dec 2024 |
| Dividend Pay Date | 24 Jan 2025 |
| Total Dividends - Year to Date | 30.06 |
| Dividend Yield (%) | 5.1297 |
Net Asset Value (Nav)
| Latest actual NAV | 610.63 |
| Latest actual NAV date | 23/04/2025 |
| NAV frequency | Daily |
| Premium/Discount | -8.4% |
Charges
|
Total Ongoing Charges
Please note that whilst we endeavour to show all charges associated with specific funds, sometimes this is not possible due to the information not being made available by the fund provider. In such cases transaction or incidental cost information may be missing. |
1.53% |
| Performance Fee | 2% |
| AMC | % |
|
Our Platform Charge
We charge a platform fee of 0.30% per annum on the value of all stocks & shares held across all accounts, minimum £50 and maximum £600 per annum, charged pro-rata monthly in arrears. A full list of our rates and charges can be found here . |
0.30% |
Cost and Charges Information
This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product
Account Type
Annual charges
These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate
| Cost Category | % of Investment | lump sum costs |
|---|---|---|
Our annual fee
Our annual feeIncludes our platform fee at 0.30% per annum (excluding Charles Stanley Multi Asset Funds and anycash held). The min fee is £60, the max is £600 per annum, plus SIPP administration fee (if applicable, only charged if < £30,000 held) – see here |
0.30% | |
Dealing charges
Dealing chargesAny one-off commission charges associated with investing. Note that government taxes and levies are not included. This does not include any commission credits you may have available |
N/A | |
Product provider costs
Product provider costsProduct provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs |
1.53% | |
Total (£)
Total (£)Costs per annum displayed in monetary value |
||
Total (%)
Total (%)Costs per annum displayed as a percentage of investment value |
||
Cumulative effect of charges on your investment's return
This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges
| lump sum invested with an assumed growth rate of | 1 year | years |
|---|---|---|
What you might get back at with no charges applied
What you might get back at with no charges appliedThese are the illustrative values of a investment after growth and no costs applied at the end of the defined period |
||
Annual charges
Annual chargesThese are the annual costs based on an initial investment amount of assuming a net zero growth rate |
||
Effect of charges on return (%)
Effect of charges on return (%)These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate |
||
Effect of charges on return (£)
Effect of charges on return (£)These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate |
||
What you might get back at with charges applied
What you might get back at with charges appliedThese are the illustrative values of a investment after growth and costs at the end of the defined period |
This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use
Company
Business Summary
International Biotechnology Trust plc is a United Kingdom-based investment trust company. The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company seeks to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with suitably experienced management and strong potential upside through the development and/or commercialization of a product, device or enabling technology. The Company’s investments may also be made in related sectors, such as medical devices and healthcare services. The Company may invest through equities, index-linked securities and debt securities, cash deposits, money market instruments and foreign currency exchange transactions. SV Health Managers LLP is the Company's alternative investment fund manager (AIFM).
Financial Summary
BRIEF: For the fiscal year ended 31 August 2024, International Biotechnology Trust Plc revenues increased from £12.1M to £44.5M. Net income increased from £6.8M to £38.9M. Revenues reflect Losses)/gains on investments held at fai increase from £7.7M to £36.2M, Unquoted investments increase from £1.9M to £5.5M, Bank interest increase from £23K to £218K. Net income benefited from Administrative expenses decrease of 37% to £834K (expense).
Performance
Cumulative Performance
| 1 month | 3 months | 6 months | 1 year | 3 years | 5 years |
| -11.48% | -18.16% | -11.83% | -1.62% | 2.97% | 9.34% |
Important Information
Headline performance can mask the true characteristics of a fund. Without fully understanding how a fund is managed, you may inadvertently become exposed to an undesirable level of risk to your capital. Some funds carry a dilution levy which reduces the number of units realised on any initial investment as an initial charge. If this fund carries such a levy it should be detailed in the Key Investor Information Document (KIID), which we must provide and you should read before investing.
The charts and performance data shown are supplied by an external data provider and may contain data that appears to precede the introduction of the clean unit class for this fund. In such cases, historical data has been synthesised at the entire discretion of that external provider as realistically as possible using historical data recorded against the previously available commission-paying version of the fund, adjusting for fees in the process.
Composition
View Fund Allocation by:
Important Documents
The documents listed below are the latest versions made available to our data provider by the fund management group, but may not necessarily reflect the applicable charges that would be levied should you purchase this fund via Charles Stanley Direct. You should treat the charges and other figures shown in the 'Overview' tab as accurate.
The Fact Sheet is supplied on a monthly basis by the management group and provides limited information on the fund. Past performance data and a review of how the fund has performed are commonly featured.
302,679 bytes PDF Document; last updated 31 Mar 2025
89,015 bytes PDF Document; last updated 19 Dec 2024
2,967,719 bytes PDF Document; last updated 31 Aug 2024
2,252,753 bytes PDF Document; last updated 29 Feb 2024
Management Team
Ailsa Craig Marek Poszepczynski
Ailsa Craig
has managed this fund for 4 years and 1 month.
Ailsa joined SV Health in 2006 and is an Investment Manager for the Trust. Ailsa has a BSc (Hons) in Biology from the University of Manchester. She was awarded the IMC in 2002 and the Securities Institute Diploma in 2007.
Manager Cumulative Performance v Peer Group
Marek Poszepczynski
has managed this fund for 4 years and 1 month.
Marek joined SV Health in 2014 and is an Investment Manager for the Trust. Marek has an MSc in Biochemistry and an MSc in Business Management from the Royal Institute of Technology, Stockholm.
Manager Cumulative Performance v Peer Group
Financials
Income Statement - All values are in GBP (M).
|
Year Ending |
31/08/2024 |
31/08/2023 |
31/08/2022 |
31/08/2021 |
31/08/2020 |
31/08/2019 |
|---|---|---|---|---|---|---|
| Total Revenue | 44.54 | 12.06 | -17.96 | 32.10 | 57.03 | -13.79 |
| Gross profit | 40.14 | 8.49 | -21.10 | 29.12 | 54.65 | -16.58 |
| Operating Profit/Loss | 39.01 | 6.94 | -22.32 | 28.05 | 53.59 | -17.44 |
| Profit Before Tax | 39.01 | 6.94 | -22.32 | 28.05 | 53.59 | -17.44 |
| Profit After Tax | 38.88 | 6.81 | -22.47 | 27.89 | 53.42 | -17.54 |
| Equity Holders of Parent Company | 38.88 | 6.81 | -22.47 | 27.89 | 53.42 | -17.54 |
| Minority Interest | NIL | NIL | NIL | NIL | NIL | NIL |
Balance Sheet - All values are in GBP (M).
|
Year Ending |
31/08/2024 |
31/08/2023 |
31/08/2022 |
31/08/2021 |
31/08/2020 |
31/08/2019 |
|---|---|---|---|---|---|---|
| Total Non-Current Assets | 297.51 | 301.90 | 313.43 | 345.34 | 302.22 | 237.36 |
| Total Current Assets | 10.65 | 2.97 | 13.49 | 2.50 | 0.49 | 3.50 |
| Total Assets | 308.16 | 304.87 | 326.92 | 347.84 | 302.71 | 240.86 |
| Total Liabilities | 25.89 | 34.55 | 42.03 | 24.06 | 18.81 | 1.28 |
| Total Net Assets | 282.27 | 270.32 | 284.89 | 323.78 | 283.90 | 239.58 |
| Shareholders Funds | 282.27 | 270.32 | 284.89 | 323.78 | 283.90 | 239.58 |
| Minority Interests | NIL | NIL | NIL | NIL | NIL | NIL |
| Total Equity | 282.27 | 270.32 | 284.89 | 323.78 | 283.90 | 239.58 |